Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

How FTSE 100 GSK (LSE:GSK) Is Accelerating Its Pipeline After Closing the $10.6bn Nuvalent Deal

The change stems from the FTSE 100 drugmaker's $10.6bnTakeoverof Nuvalent, a US developer of targeted cancer drugs, which completed on 15 July 2026. Within a week the Food and Drug Administration had approved the first medicine from the deal. At its second-quarter results in …

Ankur Sharma | 23 September 2026

Why FTSE 100 Haleon (LSE:HLN) Is Talking Up Faster Growth and Wider Margins After Its Half-Year Results

Haleon (LSE:HLN), a FTSE 100 constituent, reported sequential improvement in the second quarter, a wider adjusted operating margin, double-digit growth in adjustedEarnings Per Shareand a higher interim dividend. It also reiterated its full-year guidance. The market was not fully convinced, however, and the shares …

Ankur Sharma | 23 September 2026

How FTSE 100 Convatec (LSE:CTEC) Is Banking on a Second-Half Acceleration After Its Interim Results

Convatec (LSE:CTEC), the FTSE 100 constituent that specialises in chronic care products, published interim results on 4 August 2026. Organic growth excluding its troubled InnovaMatrix wound product was 5.0%, and the company narrowed its full-year guidance while pointing to 6% to 8% growth in …

Ankur Sharma | 23 September 2026

What Positive Enhertu Lung Cancer Trial Data Could Mean for FTSE 100 AstraZeneca (LSE:AZN)

On 14 September 2026, the FTSE 100 drugmaker and its partner Daiichi Sankyo presented full results from the DESTINY-Lung04 trial. Enhertu delivered a median progression-free survival of 14.3 months as a first-line treatment for HER2-mutant advanced non-small cell lung cancer, well ahead of the …

Ankur Sharma | 23 September 2026

Oxford Biomedica Shares Jump 6.02%: Why LSE:OXB Is Trending After Strong Client Wins and H1 Results

Oxford Biomedica became one of the most closely watched UK healthcare stocks on 22 September afterLSE:OXB climbed 6.02% to 493p. The move followed the company's interim results for the six months ended 30 June 2026, which highlighted continued revenue growth, record new-client activity and …

Ankur Sharma | 23 September 2026

Oxford Nanopore Technologies (LSE:ONT) rises 3.37%: Why is the genomics stock back in focus as AI and clinical sequencing demand accelerate?

Oxford Nanopore Technologies (LSE:ONT) closed at178.00p on 22 September 2026, representing a3.37% gainfrom the previous close. The stock opened at 173.90p, touched a low of 173.60p and reached 178.00p, finishing at the day's high.Volumewas approximately 1.8 million shares.

Ankur Sharma | 23 September 2026

Why Did Reckitt Benckiser Group PLC LSE:RKT Rise 1.19% Amid a Firmer Tone Across London-Listed Consumer Goods Shares?

Reckitt Benckiser Group PLC — LSE:RKT closed 1.19% higher on22 September 2026, with the shares at 5,038.00p after a gain of 59.00p on the day.

Ankur Sharma | 22 September 2026

Why Did Smith & Nephew PLC LSE:SN. Rise 0.29% Amid a Firmer Tone Across London-Listed Medical Devices Shares?

Smith & Nephew PLC — LSE:SN. closed 0.29% higher on22 September 2026, with the shares at 1,037.00p after a gain of 3.00p on the day.

Ankur Sharma | 22 September 2026

Why Did Bunzl PLC LSE:BNZL Rise 1.53% Amid a Firmer Tone Across London-Listed Distribution Shares?

Bunzl PLC — LSE:BNZL closed 1.53% higher on22 September 2026, with the shares at 2,654.00p after a gain of 40.00p on the day.

Ankur Sharma | 22 September 2026

Why Did Croda International PLC LSE:CRDA Rise 0.87% Amid a Firmer Tone Across London-Listed Speciality Chemicals Shares?

Croda International PLC — LSE:CRDA closed 0.87% higher on22 September 2026, with the shares at 3,237.00p after a gain of 28.00p on the day.

Ankur Sharma | 22 September 2026
Support

Hi! How can we help you today?

Loading…